TheraCryf (LSE:TCF) YoY EBITDA Growth: 66.67% (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is TheraCryf YoY EBITDA Growth?

TheraCryf LSE:TCF YoY EBITDA Growth is 66.67% as of Sep. 2025. The stock has 3 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. TheraCryf's YoY EBITDA Growth for the quarter that ended in Sep. 2025 was 66.67%.

TheraCryf's EBITDA per Share for the six months ended in Sep. 2025 was £-0.00.

TheraCryf YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for TheraCryf's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TheraCryf YoY EBITDA Growth Chart

TheraCryf Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.50 42.86 -50.00 27.78 69.23

TheraCryf Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.50 20.00 40.00 87.50 66.67

TheraCryf YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

TheraCryf's YoY EBITDA Growth for the fiscal year that ended in Mar. 2025 is calculated as:

YoY EBITDA Growth (A: Mar. 2025 )
=(EBITDA per Share (A: Mar. 2025 )-EBITDA per Share (A: Mar. 2024 ))/ | EBITDA per Share (A: Mar. 2024 ) |
=(-0.004--0.013)/ | -0.013 |
=69.23 %

TheraCryf's YoY EBITDA Growth for the quarter that ended in Sep. 2025 is calculated as:

YoY EBITDA Growth (Q: Sep. 2025 )
=(EBITDA per Share (Q: Sep. 2025 )-EBITDA per Share (Q: Sep. 2024 )) / | EBITDA per Share (Q: Sep. 2024 )) |
=(-0.001--0.003)/ | -0.003 |
=66.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 66.67% mean?
TheraCryf (LSE:TCF) has a YoY EBITDA Growth of 66.67% as of Sep. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for TheraCryf and its competitors.
Is TheraCryf's YoY EBITDA Growth too high?
TheraCryf's current YoY EBITDA Growth is 66.67%.
How does TheraCryf's YoY EBITDA Growth compare to VRTX and REGN?
TheraCryf's YoY EBITDA Growth of 66.67% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for TheraCryf and its competitors. TheraCryf's current YoY EBITDA Growth is 66.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TheraCryf stock overvalued right now?
TheraCryf (LSE:TCF) has a current YoY EBITDA Growth of 66.67%. The current YoY EBITDA Growth is 66.67%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For TheraCryf (LSE:TCF), the current YoY EBITDA Growth is 66.67% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TheraCryf Business Description

Address Congleton Road, Alderley Park, Nether Alderley, Cheshire, GBR, SK10 4TG
TheraCryf PLC is a clinical stage therapeutics company developing therapeutic candidates for behavioural brain disorders such as opioid and alcohol addiction, and acute/chronic fatigue. It focuses on data generation to support potential partnerships for its programs with mid-sized and large pharmaceutical companies. The company's pipeline includes Ox-1 - Substance Use Disorders (SUDs) / Anxiety, DAT - Fatigue and Narcolepsy, SFX-01, and SFX-01- Neurodevelopmental Disorders.